Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Needham Reiterates Buy on Verrica Pharmaceuticals, Maintains $8 Price Target

Author: Benzinga Newsdesk | April 10, 2024 06:58am
Needham reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and maintains $8 price target.

Posted In: VRCA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist